Replies to post #18244 on Vilacto Bio Inc (fka VIBI)

[beer$$money]

The Multi $$$ Billion Nanoparticle Pharmaceutical Patent VIBI holds to me is the real Connection here to Cantabio IMO. Cantabio was highlighted in this year’s World Economic Forum report titled “Top 10 Emerging Technologies 2019” as one of the top 10 emerging world-changing technologies for 2019.

Cantabio was described as one of few leading companies in the world capable of therapeutically targeting intrinsically disordered proteins, a special class of promising drug targets for Alzheimer’s and cancer. The report identified Cantabio’s particular ability to target these types of proteins, previously considered by the pharmaceutical industry as impossible to target, for the development of promising new drugs in the areas of neurodegeneration and cancer.
https://www.cantabio.com/news-media/cantabio-in-the-news.html

What does VIBI bring to the pharmaceutical industry??

LACTOACTIVE iTHER® compound:
The LACTOACTIVE iTHER® compound will also enable the pharmaceutical companies we partner with to embed our potent compounds in their own immunotherapy and vaccine innovations. Emerging therapies for treating cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and vitiligo all stand to benefit.
Thanks to is nanoparticle form, the compound also acts as an injectable nanoparticle drug delivery system (NDDS), able to penetrate affected cell walls and enter the cytoplasm to do its work.

1. The particles consist of refined colostrum and other ingredients that both contain vital antibodies and stimulate the immune system to fight diseases.

2. LACTOACTIVE iTHER® can be directed into the affected cells, where it boosts the immune system’s response to the disease in question.

3. No other biotech firm has managed to “weaponize” colostrum so effectively.

4. Vilacto Bio holds the worldwide patent for LACTOACTIVE iTHER®.

PATENTS AND INTELLECTUAL PROPERTY RIGHTS
We protect our proprietary therapeutic products, assets and technologies by seeking and maintaining both domestic and international patent rights. These may cover products, compositions, methods of use, manufacturing processes, and other inventions that may be important to our business strategy. We also rely on trade secrets to protect aspects of our business.


According to Patent No 8,637,075. a nanoparticle composition comprising colostrum Lactoactive® is formulated for treating diseases and/or conditions. Relieving the limited status due to the poor mechanical properties, rapid degradation, and in vivo clearance when bovine colostrum is used, our Lactoactive® is valuable to modify new bio/pharmaceutical industries.

In connection with our programs under Topical Drug, Systemic Drug & Supplement, and Cosmetics we hold a worldwide, perpetual, non-exclusive, license, with the right to sublicense, all the intellectual property related to the composition of matter of Topical Drug, Systemic Drug & Supplement and Cosmetics and plan to file U.S. and international patent applications.
https://vilactobio.com/ip-patent-rights/

This has been brought to the Boards Attention:
Both Companies share the same contact info:

Vilacto Bio Inc. is a preclinical stage biotechnology company focusing on commercializing novel biopharmaceutical therapies, cosmeceutical products, ingredient production services with the intellectual property generated from our research and formulations and development activities based on Lactoactive® for any possible purpose.

Company Info
Address:
1250 Oakmead Pkwy
Sunnyvale, CA 94085 US
Toll-Free IR Helpline:
(844) 200-CTBO
Email:
[e-mail]
https://vilactobio.com/profile/


Cantabio Pharmaceuticals Inc.
2225 East Bayshore Road
Palo Alto, CA 94303
Main Office: 844-200-2826
[e-mail]
https://www.cantabio.com/contact.html

Investor Relations
(844) 200-CTBO
[e-mail]

@cantabio

Following DD I believe is New to the Board?

If you go to the Twitter account for Cantabio you find a date that they dropped off the Grid? Nov 13, 2019· All Parties here went "QUITE" at this time.

Last Official Tweet
Cantabio@cantabio
The official corporate Twitter feed for Cantabio. We aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.
Tweet

Study led by @Cantabio
demonstrates for the first time that the aggregation of DJ-1 is an important component in the pathology of #Parkinsons and #Alzheimers disease - supporting DJ-1 as a therapeutic target https://sciencedirect.com/science/article/pii/S0969996119303043
9:32 AM · Nov 13, 2019·Twitter

Study led by @Cantabio demonstrates for the first time that the aggregation of DJ-1 is an important component in the pathology of #Parkinsons and #Alzheimers disease - supporting DJ-1 as a therapeutic target https://t.co/vN1FwnwnBy pic.twitter.com/A2rMtrT1Tg

— Cantabio Pharmaceuticals (@cantabio) November 13, 2019

VIBI Filed NT 10-Q 11/14/2019 for 09/30/2019
That was never Filed & the Last time we heard anything from VIBI??

https://www.otcmarkets.com/stock/VIBI/disclosure

Last SEC filing from CBTO 15-12G 06/21/2019
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g
This was a week before the “Top 10 Emerging Technologies 2019 Award."

https://www.otcmarkets.com/stock/CTBO/disclosure

When will Cantabio cease to be an SEC reporting public company?

The reverse stock split, the filing of Form 15 and the resulting termination of the registration of our common stock and the termination of our duty to file reports with the SEC are sometimes referred to collectively in this information statement as the "going private" transaction.


What are some of the advantages of the reverse stock split?

*Terminating the registration of our common stock will eliminate the expenses and our officers' and employees' time and effort related to our registration and periodic reporting obligations under the Securities Exchange Act of 1934, as amended, and the related stockholder servicing expenses associated with being an SEC reporting company and subject the Sarbanes-Oxley Act of 2002, which are estimated to be in excess of $130,000 annually.

*Providing access to potential investors that do not invest in publicly held companies.


Cantabio has been publicly held for several years; what are some of the reasons for "going private" now?

Our board of directors believes that Cantabio currently derives no material benefit from its public company status.


Cantabio does not believe that it could obtain the necessary financing to continue operations without going private.

We have spoken to potential investors willing to provide such a financing, but they have indicated to us that they would not be able to do so if we were a public company. Although we have not entered into any binding agreements for such a financing, we did undertake a short-term financing with our director, Max Zhu,


https://www.otcmarkets.com/filing/html?id=13454632&guid=1RgqUFTR108rfth

The largest Cantabio shareholder & director, Max Zhu, discontinued his linkedIn account a year ago in Nov 2019?? My speculation is "They" Cantabio & VIBI don't want anything to get out on what has developed until they are ready to announce those details??

From this LinkedIn page you can see his comments stopped a year ago?
Account D. commented on this 1yr ago.

Marianne Stemann Andersen

Marianne from Denmark?
Ph.D. Stem Cell Biology - M.Sc. Human Biology - MBA. Bio(Tech & Pharma)Business
Copenhagen, Capital Region, Denmark 440 connections


https://www.linkedin.com/posts/8msa8_tracing-the-cellular-dynamics-of-sebaceous-activity-6561703318622650368-XEyv

Max Zhu, Ph.D. Largest Shareholder Cantabio
Cantabio Pharmaceuticals Inc.
Chief Business Development Officer

Account Discontinued
United States 346 connections

University of Cambridge
Cambridge, England

Drug Design
Alzheimer's Disease
Parkinson's Disease


When you look at his Companies of Interest you will find Cantabio & Gardedam Therapeutics as well as many other Huge Pharma Companies.


A Few Companies of Interest
https://www.linkedin.com/in/max-zhu/detail/interests/companies/

You have to scroll all the way toward the Bottom to find Catabio.
Cantabio Pharmaceuticals, Inc.
Pharmaceuticals Sunnyvale, CA 323 followers
Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.

Gardedam Therapeutics Inc.
Biotechnology San Francisco, CA

You can now find Max Z here on Cantabio Employee page:
https://www.linkedin.com/in/max-z-2684a2192/

THINGS TO CONSIDER DURING BLACKOUT AND QUIET PERIODS

A quiet period is an interval in time when corporate insiders need to limit their interaction with the public due to the insiders' knowledge of material information. Typically, this applies to a period when management has knowledge regarding company news that has not been announced to the public. Quiet periods exist in order to avoid the potential of a company selectively disclosing – or appearing to disclose – non-public information. The intention of blackout periods is to prevent any corporate insiders from making comments – or even unintentional implications – that would cause investors to alter their investment positions before any information is disseminated to the public.


https://gilmartinir.com/things-to-consider-during-blackout-and-quiet-periods/

So Silence is Golden to those that are Listening!!